// App-Quantinova.ai

e14076 : MRX34, a liposomal miR-34 mimic and potential first-in-class microRNA therapeutic: activity in animal models of liver cancer.

Researchers

Presenter

  • Chris Daige

Principal Investigators

  • Leslie Priddy

  • Jason Wiggins

  • Terri Nelligan-Davis

  • Danlee Enzler

  • Komal Vadnagara

  • David Brown

Medical Centers

  • Mirna Therapeutics Inc, Austin, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Central Nervous System (CNS)

Disease

  • Liver cancer

  • Solid malignancies

  • Mental retardation, X-linked 21

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Sorafenib

  • MRX34

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved